Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
Li-Chuan Chan, … , Shao-Chun Wang, Mien-Chie Hung
Li-Chuan Chan, … , Shao-Chun Wang, Mien-Chie Hung
Published July 15, 2019
Citation Information: J Clin Invest. 2019;129(8):3324-3338. https://doi.org/10.1172/JCI126022.
View: Text | PDF
Research Article Cell biology Oncology Article has an altmetric score of 70

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion

  • Text
  • PDF
Abstract

Glycosylation of immune receptors and ligands, such as T cell receptor and coinhibitory molecules, regulates immune signaling activation and immune surveillance. However, how oncogenic signaling initiates glycosylation of coinhibitory molecules to induce immunosuppression remains unclear. Here we show that IL-6–activated JAK1 phosphorylates programmed death-ligand 1 (PD-L1) Tyr112, which recruits the endoplasmic reticulum–associated N-glycosyltransferase STT3A to catalyze PD-L1 glycosylation and maintain PD-L1 stability. Targeting of IL-6 by IL-6 antibody induced synergistic T cell killing effects when combined with anti–T cell immunoglobulin mucin-3 (anti–Tim-3) therapy in animal models. A positive correlation between IL-6 and PD-L1 expression was also observed in hepatocellular carcinoma patient tumor tissues. These results identify a mechanism regulating PD-L1 glycosylation initiation and suggest the combination of anti–IL-6 and anti–Tim-3 as an effective marker-guided therapeutic strategy.

Authors

Li-Chuan Chan, Chia-Wei Li, Weiya Xia, Jung-Mao Hsu, Heng-Huan Lee, Jong-Ho Cha, Hung-Ling Wang, Wen-Hao Yang, Er-Yen Yen, Wei-Chao Chang, Zhengyu Zha, Seung-Oe Lim, Yun-Ju Lai, Chunxiao Liu, Jielin Liu, Qiongzhu Dong, Yi Yang, Linlin Sun, Yongkun Wei, Lei Nie, Jennifer L. Hsu, Hui Li, Qinghai Ye, Manal M. Hassan, Hesham M. Amin, Ahmed O. Kaseb, Xin Lin, Shao-Chun Wang, Mien-Chie Hung

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2009 Total
Citations: 16 41 30 37 43 25 2 1 195
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2024 (41)

Title and authors Publication Year
Biology Driven Therapy Advances in High Grade Serous Ovarian Cancer
Yinu Wang, Alexander James Duval, Mazhar Adli, Daniela Matei
Journal of Clinical Investigation 2024
Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy.
Kim SB, Hwang S, Cha JY, Lee HJ
International journal of molecular sciences 2024
BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1.
Kim YS, Lee SH, Park AH, Wu C, Hong BK, Jung H, Lin SH, Yoo SS
Journal for ImmunoTherapy of Cancer 2024
Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy.
Lee TA, Tsai EY, Liu SH, Hsu Hung SD, Chang SJ, Chao CH, Lai YJ, Yamaguchi H, Li CW
Cancer research 2024
Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer
Haq AT, Yang PP, Jin C, Shih JH, Chen LM, Tseng HY, Chen YA, Weng YS, Wang LH, Snyder MP, Hsu HL
Theranostics 2024
IL-6-Derived Autocrine Lactate Promotes Immune Escape of Uveal Melanoma
Gong C, Yang M, Long H, Liu X, Xu Q, Qiao L, Dong H, Liu Y, Li S
Investigative ophthalmology & visual science 2024
Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1
Dillen A, Bui I, Jung M, Agioti S, Zaravinos A, Bonavida B
Cancers 2024
Cancer stem cell-immune cell crosstalk in the tumor microenvironment for liver cancer progression.
Ma Y, Lv H, Xing F, Xiang W, Wu Z, Feng Q, Wang H, Yang W
Frontiers of Medicine 2024
Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways
Wang R, He S, Long J, Wang Y, Jiang X, Chen M, Wang J
Experimental Hematology and Oncology 2024
The Role of Coinhibitory Receptors in B Cell Dysregulation in SARS-CoV-2–Infected Individuals with Severe Disease
Saito S, Bozorgmehr N, Sligl W, Osman M, Elahi S
2024
PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy
Ren X, Wang L, Liu L, Liu J
Frontiers in immunology 2024
The IL-6 signaling pathway contributes critically to the immunomodulatory mechanism of human decidua-derived mesenchymal stromal cells
Na H, Im KI, Kim N, Lee J, Gil S, Min GJ, Cho SG
iScience 2024
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, Yi M, Xiang B
Molecular Cancer 2024
The Role of JAK-STAT-SOCS1 Axis in Tumorigenesis, Malignant Progression and Lymphatic Metastasis of Penile Cancer.
Xu DM, Chen LX, Zhuang XY, Han H, Mo M
International journal of medical sciences 2024
FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma.
Wang Q, Tan W, Zhang Z, Chen Q, Xie Z, Yang L, Tang C, Zhuang H, Wang B, Jiang J, Ma X, Wang W, Hua Y, Shang C, Chen Y
Apoptosis : an international journal on programmed cell death 2024
Senescence-Associated Secretory Phenotype (SASP) and Uterine Fibroids: Association with PD-L1 Activation and Collagen Deposition
Saad EE, Michel R, Borahay MA
Ageing Research Reviews 2024
EZH2 Inhibition Enhances PD‐L1 Protein Stability Through USP22‐Mediated Deubiquitination in Colorectal Cancer
Huang J, Yin Q, Wang Y, Zhou X, Guo Y, Tang Y, Cheng R, Yu X, Zhang J, Huang C, Huang Z, Zhang J, Guo Z, Huo X, Sun Y, Li Y, Wang H, Yang J, Xue L
Advanced Science 2024
Predictive and prognostic value of aurora kinase A combined with tumor-infiltrating lymphocytes in medullary thyroid carcinoma
Wang Z, Guo F, Fu G, Zhao Z, Kang N, Hou X, Zheng X
Frontiers in Oncology 2024
PDL1 targeting by miR-138-5p amplifies anti-tumor immunity and Jurkat cells survival in non-small cell lung cancer
Rostami F, Tavakol Hamedani Z, Sadoughi A, Mehrabadi M, kouhkan F
Scientific Reports 2024
High expression of BTN3A1 is associated with clinical and immunological characteristics and predicts a poor prognosis in advanced human gliomas
Kone AS, Ghouzlani A, Qandouci A, Issam Salah NE, Bakoukou Y, Lakhdar A, Karkouri M, Badou A
Frontiers in immunology 2024
Targeting cancer-associated fibroblast autophagy renders pancreatic cancer eradicable with immunochemotherapy by inhibiting adaptive immune resistance
Zhang X, Lao M, Yang H, Sun K, Dong Y, He L, Jiang X, Wu H, Jiang Y, Li M, Ying H, Liu X, Xu J, Chen Y, Zhang H, Zhou R, Gao J, Bai X, Liang T
Autophagy 2024
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, Dai Z
Signal Transduction and Targeted Therapy 2024
N-linked glycosylation of PD-L1/PD-1: an emerging target for cancer diagnosis and treatment.
Duan Z, Shi R, Gao B, Cai J
Journal of Translational Medicine 2024
Glycosylation and Its Role in Immune Checkpoint Proteins: From Molecular Mechanisms to Clinical Implications.
Liu J, Xu X, Zhong H, Yu M, Abuduaini N, Zhang S, Yang X, Feng B
Biomedicines 2024
Elucidating the multifaceted role of MGAT1 in hepatocellular carcinoma: integrative single-cell and spatial transcriptomics reveal novel therapeutic insights
Li Y, Chen Y, Wang D, Wu L, Li T, An N, Yang H
Frontiers in immunology 2024
Revealing the crucial roles of suppressive immune microenvironment in cardiac myxoma progression.
Jiang Z, Kang Q, Qian H, Xu Z, Tong H, Yang J, Li L, Li R, Li G, Chen F, Lin N, Zhao Y, Shi H, Huang J, Ma X
Signal Transduction and Targeted Therapy 2024
Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer
He P, Ma L, Xu B, Wang Y, Li X, Chen H, Li Y
Therapeutic advances in medical oncology 2024
Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics
Tang J, Liu H, Li J, Zhang Y, Yao S, Yang K, You Z, Qiao X, Song Y
Future Medicinal Chemistry 2024
CTDSPL2 promotes the progression of non-small lung cancer through PI3K/AKT signaling via JAK1
Li M, Chen L, Yu F, Mei H, Ma X, Ding K, Yang Y, Rong Z
Cell Death Discovery 2024
Insights into the Interplay between the Urinary Microbiome and Bladder Cancer: A Comprehensive Review
Pallares-Mendez R, Brassetti A, Bove AM, Simone G
Journal of Clinical Medicine 2024
Defective N-glycosylation of IL6 induces metastasis and tyrosine kinase inhibitor resistance in lung cancer
Hung CH, Wu SY, Yao CI, Yeh HH, Lin CC, Chu CY, Huang TY, Shen MR, Lin CH, Su WC
Nature Communications 2024
Hexavalent chromium exposure activates the non-canonical nuclear factor kappa B pathway to promote immune checkpoint protein programmed death-ligand 1 expression and lung carcinogenesis
Wang PS, Liu Z, Sweef O, Saeed AF, Kluz T, Costa M, Shroyer KR, Kondo K, Wang Z, Yang C
Cancer letters 2024
Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics.
Cai M, Xu M, Yu D, Wang Q, Liu S
Acta biochimica et biophysica Sinica 2024
PKCα inhibitors promote breast cancer immune evasion by maintaining PD-L1 stability
Yu J, Xiang Y, Gao Y, Chang S, Kong R, Lv X, Yu J, Jin Y, Li C, Ma Y, Wang Z, Zhou J, Yuan H, Shang S, Hua F, Zhang X, Cui B, Li P
Acta Pharmaceutica Sinica. B 2024
Unlocking the dual role of LSD1 in tumor immunity: innate and adaptive pathways
Zhang Y, Guo N, Zhu H, Liu M, Hao J, Wang S, Guo T, Mamun M, Pang J, Liu Q, Zheng Y, Liu H, Si P, Zhao L
Theranostics 2024
Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy
Godiyal Y, Maheshwari D, Taniguchi H, Zinzuwadia SS, Morera-Díaz Y, Tewari D, Bishayee A
Military Medical Research 2024
Distribution and clinicopathological characteristics of G-CSF expression in tumor cells and stromal cells in upper tract urothelial carcinoma
Kobayashi G, Sekino Y, Nakahara H, Kobatake K, Goto K, Hayashi T, Sentani K, Hinata N
Journal of Cancer Research and Clinical Oncology 2024
T-cell Receptor Repertoire Analysis in the Context of Transarterial Chemoembolization Synergy with Systemic Therapy for Hepatocellular Carcinoma
Li J, Zhang Y, Hu L, Ye H, Yan X, Li X, Li Y, Ye S, Wu B, Li Z
Journal of Clinical and Translational Hepatology 2024
Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors
Hernández\u2010Prat A, Rodriguez\u2010Vida A, Cardona L, Qin M, Arpí\u2010Llucià O, Soria\u2010Jiménez L, Menendez S, Quimis FG, Galindo M, Arriola E, Salido M, Juanpere\u2010Rodero N, Rojo F, Muntasell A, Albanell J, Rovira A, Bellmunt J
Molecular Oncology 2024
Artificial intelligence-based multi-modal multi-tasks analysis reveals tumor molecular heterogeneity, predicts preoperative lymph node metastasis and prognosis in papillary thyroid carcinoma: a retrospective study
Yu Y, Ouyang W, Huang Y, Huang H, Wang Z, Jia X, Huang Z, Lin R, Zhu Y, yalikun Y, Tan L, Li X, Zhao F, Chen Z, Li W, Liao J, Yao H, Long M
International Journal of Surgery (London, England) 2024
A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma.
Guo X, Cui T, Sun L, Fu Y, Cheng C, Wu C, Zhu Y, Liang S, Liu Y, Zhou S, Li X, Ji C, Ma K, Zhang N, Chu Q, Xing C, Deng S, Wang J, Liu Y, Liu L
Cell death and differentiation 2024

← Previous 1 2 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 10 news outlets
Posted by 9 X users
Referenced in 1 patents
155 readers on Mendeley
See more details